Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PARA
Paramount Global Class B
PARA
|
+$75M |
| 2 |
Chevron
CVX
|
+$59.9M |
| 3 |
GE HealthCare
GEHC
|
+$57.5M |
| 4 |
Applovin
APP
|
+$54.7M |
| 5 |
OKLO
Oklo
OKLO
|
+$52.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xcel Energy
XEL
|
+$137M |
| 2 |
Meta Platforms (Facebook)
META
|
+$61.8M |
| 3 |
Becton Dickinson
BDX
|
+$59.9M |
| 4 |
CRWV
CoreWeave
CRWV
|
+$57.1M |
| 5 |
Apple
AAPL
|
+$50.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.73% |
| 2 | Financials | 9.81% |
| 3 | Utilities | 8.63% |
| 4 | Technology | 7.6% |
| 5 | Industrials | 7.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Olema Pharmaceuticals
OLMA
$913M
| $251K | ﹤0.01% |
+58,980
| New | +$263K |
|
1277
PDF Solutions
PDFS
$1.86B
| $250K | ﹤0.01% |
+11,716
| New | +$222K |
|
|
ZK
1278
DELISTED
Zeekr
ZK
| $244K | ﹤0.01% |
+9,567
| New | +$236K |
|
1279
Iridium Communications
IRDM
$5.01B
| $241K | ﹤0.01% |
7,976
-152,148
| -95% | -$3.96M |
|
|
SAGE
1280
DELISTED
Sage Therapeutics
SAGE
| $238K | ﹤0.01% |
26,125
-53,235
| -67% | -$392K |
|
1281
dLocal
DLO
$4.45B
| $237K | ﹤0.01% |
+20,917
| New | +$206K |
|
1282
Standex International
SXI
$3.67B
| $237K | ﹤0.01% |
+1,513
| New | +$227K |
|
1283
JELD-WEN Holding
JELD
$216M
| $235K | ﹤0.01% |
+59,897
| New | +$267K |
|
1284
Clarivate
CLVT
$1.36B
| $234K | ﹤0.01% |
54,309
-289,362
| -84% | -$1.17M |
|
1285
Hyster-Yale Materials Handling
HY
$614M
| $232K | ﹤0.01% |
5,822
-13,874
| -70% | -$553K |
|
1286
Alamos Gold
AGI
$16B
| $231K | ﹤0.01% |
8,699
-122,160
| -93% | -$3.27M |
|
|
AMTM
1287
Amentum Holdings
AMTM
$4.9B
| $231K | ﹤0.01% |
+9,801
| New | +$205K |
|
1288
Equinox Gold
EQX
$16.1B
| $230K | ﹤0.01% |
+39,930
| New | +$259K |
|
1289
GameStop
GME
$8.09B
| $230K | ﹤0.01% |
9,434
-11,227
| -54% | -$301K |
|
1290
Recursion Pharmaceuticals
RXRX
$1.74B
| $230K | ﹤0.01% |
+45,413
| New | +$223K |
|
1291
Unisys
UIS
$192M
| $228K | ﹤0.01% |
50,370
+19,927
| +65% | +$89.6K |
|
1292
AerSale
ASLE
$268M
| $227K | ﹤0.01% |
37,812
+27,288
| +259% | +$175K |
|
1293
Byrna Technologies
BYRN
$82.5M
| $227K | ﹤0.01% |
+7,343
| New | +$179K |
|
|
ABX
1294
Abacus Global Management
ABX
$940M
| $226K | ﹤0.01% |
+44,030
| New | +$325K |
|
|
SEG
1295
Seaport Entertainment Group
SEG
$348M
| $226K | ﹤0.01% |
+12,120
| New | +$233K |
|
1296
Bread Financial
BFH
$4.04B
| $224K | ﹤0.01% |
+3,919
| New | +$198K |
|
|
INGM
1297
Ingram Micro Holding
INGM
$6.41B
| $224K | ﹤0.01% |
+10,746
| New | +$200K |
|
|
INZY
1298
DELISTED
Inozyme Pharma
INZY
| $222K | ﹤0.01% |
+55,515
| New | +$137K |
|
1299
Oscar Health
OSCR
$9.82B
| $220K | ﹤0.01% |
10,283
-171,861
| -94% | -$2.55M |
|
|
ELEV
1300
DELISTED
Elevation Oncology
ELEV
| $219K | ﹤0.01% |
+597,017
| New | +$199K |
|
Similar funds
Michael Gelband's Q2 2025 Portfolio in Review
As of Q2 2025, Michael Gelband held 2,093 positions worth $11.4B, up 13% from $10.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Michael Gelband deployed $528M of net new capital in Q2 2025, opening 704 new positions and adding to 330 existing holdings. Its largest new stake was Chevron: 424,949 shares worth $60.8M.
By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier, followed by Financials and Utilities.
On the sell side, the largest reduction was Xcel Energy, an estimated $137M trimmed.
- Michael Gelband's largest Q2 2025 buy was Chevron: 424,949 shares worth $60.8M.
- Michael Gelband added most to Paramount Global Class B in Q2 2025, an estimated $75M increase.
- Michael Gelband's biggest Q2 2025 reduction was Xcel Energy, cutting an estimated $137M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q2 2025, selling an estimated $61.8M.
- Michael Gelband's ten largest holdings make up 25% of its $11.4B portfolio in Q2 2025.
- Michael Gelband opened 704 new positions and closed 687 in Q2 2025.
- Michael Gelband's portfolio value rose 13% quarter-over-quarter to $11.4B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.